Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

BACKGROUND: PD-1/PD-L1 inhibitors have significantly improved the outcomes of those patients with various malignancies. However, the incidence of adverse events also increased. This meta-analysis aims to systematically evaluate the risk of cardiovascular toxicity in patients treated with PD-1/PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Surui, Gao, Wei, Ning, Yan, Zou, Xiaomeng, Zhang, Weike, Zeng, Liangjie, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307961/
https://www.ncbi.nlm.nih.gov/pubmed/35880172
http://dx.doi.org/10.3389/fimmu.2022.908173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307961/
https://www.ncbi.nlm.nih.gov/pubmed/35880172
http://dx.doi.org/10.3389/fimmu.2022.908173

Ejemplares similares